<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01423656</url>
  </required_header>
  <id_info>
    <org_study_id>LEO 29102-C06</org_study_id>
    <nct_id>NCT01423656</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Pharmacokinetic Study in Healthy Subjects by Dermal Application of a LEO 29102</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The principal aim of this study is to obtain safety, tolerability and pharmacokinetic data&#xD;
      when LEO 29102 is administered cutaneously as single and multiple doses to healthy subjects.&#xD;
&#xD;
      The study is divided into one single dose part, one part to compare pharmacokinetics between&#xD;
      gender and one multiple dose part.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with adverse events (AEs) and change from baseline in vital signs (blood pressure, pulse rate, respiratory rate and oral body temperature), ECG, telemetry,clinical laboratory and local tolerability assessments</measure>
    <time_frame>7 days after last dosing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>LEO 29102 and metabolites in blood and urine</measure>
    <time_frame>72 hours after dosing</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>LEO 29102</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>LEO 29102 vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEO 29102</intervention_name>
    <arm_group_label>LEO 29102</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Comparator: LEO 29102 vehicle</description>
    <arm_group_label>LEO 29102 vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects will be Caucasian males and females between 18 and 55 years of age and with a&#xD;
             body mass index (BMI) between 18.0 and 30.0 kg/m2 inclusive.&#xD;
&#xD;
          -  Subjects must be in good health, as determined by a medical history, physical&#xD;
             examination, 12-lead electrocardiogram (ECG) and clinical laboratory evaluations&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who suffer from, or show signs of eczema or other skin lesions.&#xD;
&#xD;
          -  Subjects who are still participating in a clinical study (e.g. attending follow-up&#xD;
             visits) or who have participated in a clinical study involving administration of an&#xD;
             investigational drug (new chemical entity), or a marketed drug within the past 3&#xD;
             months prior to the first dosing occasion.&#xD;
&#xD;
          -  Subjects with a significant history of drug allergy as determined by the Investigator.&#xD;
&#xD;
          -  Subjects with known immunocompromised state due to treatment with immunosuppressive&#xD;
             drugs or due to history of a disease leading to immunocompromised status.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ashley Brooks, MBChB</last_name>
    <role>Principal Investigator</role>
    <affiliation>Covance</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical Research Unit Ltd.</name>
      <address>
        <city>Leeds</city>
        <zip>LS2 9LH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>July 14, 2011</study_first_submitted>
  <study_first_submitted_qc>August 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2011</study_first_posted>
  <last_update_submitted>January 25, 2013</last_update_submitted>
  <last_update_submitted_qc>January 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

